Lupin Ltd.
Clinical trials sponsored by Lupin Ltd., explained in plain language.
-
New Once-a-Day pill tested for rare muscle locking disorder
Symptom relief Recruiting nowThis study is testing if a new, once-daily version of the drug mexiletine works as well and is as safe as the current three-times-daily version for adults with rare inherited muscle stiffness disorders (non-dystrophic myotonias). 24 participants will try both versions for 12 week…
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Mar 30, 2026 14:29 UTC
-
New hope for easing debilitating muscle lock in rare disease
Symptom relief Recruiting nowThis study is testing whether a daily, extended-release version of the drug mexiletine can safely reduce muscle stiffness (myotonia) in people with myotonic dystrophy types 1 and 2. About 176 participants will take either the real drug or a placebo for 26 weeks to see if it helps…
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Mar 27, 2026 12:38 UTC
-
Tracking a muscle Drug's safety in the youngest patients
Knowledge-focused Recruiting nowThis study aims to collect long-term safety and usage information on the drug mexiletine in children under 6 years old who have myotonic disorders, which cause stiff muscles. Doctors will observe and record data from about 10 children already receiving this treatment as part of t…
Sponsor: Lupin Ltd. • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC